Although nitric oxide (NO) signaling promotes differentiation and maturation of endothelial progenitor cells, its role in the differentiation of mesenchymal stem cells (MSCs) into endothelial cells remains controversial. We tested the role of NO signaling in MSCs derived from WT mice and mice homozygous for a deletion of S-nitrosoglutathione reductase (GSNOR −/− ), a denitrosylase that regulates S-nitrosylation. GSNOR −/− MSCs exhibited markedly diminished capacity for vasculogenesis in an in vitro Matrigel tube-forming assay and in vivo relative to WT MSCs. This decrease was associated with down-regulation of the PDGF receptorα (PDGFRα) in GSNOR −/− MSCs, a receptor essential for VEGF-A action in MSCs. Pharmacologic inhibition of NO synthase with L-N G -nitroarginine methyl ester (L-NAME) and stimulation of growth hormone-releasing hormone receptor (GHRHR) with GHRH agonists augmented VEGF-A production and normalized tube formation in GSNOR −/− MSCs, whereas NO donors or PDGFR antagonist reduced tube formation ∼50% by murine and human MSCs. The antagonist also blocked the rescue of tube formation in GSNOR −/− MSCs by L-NAME or the GHRH agonists JI-38, MR-409, and MR-356. Therefore, GSNOR −/− MSCs have a deficient capacity for endothelial differentiation due to downregulation of PDGFRα related to NO/GSNOR imbalance. These findings unravel important aspects of modulation of MSCs by VEGF-A activation of the PDGFR and illustrate a paradoxical inhibitory role of S-nitrosylation signaling in MSC vasculogenesis. Accordingly, disease states characterized by NO deficiency may trigger MSC-mediated vasculogenesis. These findings have important implications for therapeutic application of GHRH agonists to ischemic disorders.
angiogenesis | nitroso-redox imbalance N itric oxide (NO) and VEGF signaling promotes vasculogenesis by endothelial progenitor cells (EPCs) (1) (2) (3) (4) (5) . For example, mice deficient in endothelial NO synthase (NOS3 −/− ) show reduced VEGF-induced mobilization of bone marrow progenitor cells to sites of injury (4) . In EPC-mediated vasculogenesis, VEGF-A activates its major receptor [VEGF receptor 2 (VEGFR2)], triggering cell differentiation into mature endothelial cells (ECs) and enhancing angiogenesis (6, 7) .
Mesenchymal stem cells (MSCs) also participate in postnatal angiogenesis (8, 9) , and vascular pericytes, which are crucial for maintaining vascular integrity, share similar phenotypic features with MSCs (10). Exogenously administered, MSCs readily form new capillaries and medium-sized arteries (11, 12) , properties important for the tissue regenerative capacity of MSCs (13) . We and others have shown that MSCs differentiate into endothelial cells in vitro (14) and in vivo and contribute to neovascularization, particularly during tissue ischemia and tumor vascularization (8, 11, 12, 15) . As with EPCs, VEGF also plays an important role in stimulating MSC differentiation, but does so by activating the PDGF receptor (PDGFR) as opposed to the VEGFR2, which is absent on MSCs (16) . However, the impact of NO signaling in the differentiation of MSCs into endothelial cells has not been previously tested. Given the similar signaling involved in endothelial differentiation of EPCs and MSCs, we reasoned that NO plays an equivalent role in this process.
Accordingly, we tested the hypothesis that NO signaling, mediated by small molecular weight thiols (molecular weight < 500), promotes MSC differentiation into endothelial cells. To test our hypothesis, we assessed the functional consequences of deletion of S-nitrosoglutathione reductase (GSNOR), which in turn increases S-nitrosothiols (17, 18), on MSC-mediated vasculogenesis. We report that paradoxically, MSCs from GSNOR −/− mice exhibit diminished endothelial differentiation, thereby demonstrating an inhibitory effect of S-nitrosylation on vasculogenesis mediated by MSCs.
Results
Murine Bone Marrow MSC Characterization. Both WT and GSNOR −/− -derived MSCs were spindle shaped, adherent to plastic tissue culture dishes (Fig. S1A) , and negative for Lineage, a mixture of hematopoietic markers, CD34 and CD45, and positive for stem cell antigens SCA-1, CD73, CD90.2, and CD105 ( Fig. S1 B and C) .
NO Signaling and MSCs. Denitrosylation is controlled in significant part by GSNOR, a unique and specific enzyme for which S-nitrosoglutathione (GSNO) is the substrate (18) (Fig. S2A ). Neither MSCs (Fig. S2 B and C) nor liver (Fig. S2D ) from GSNOR −/− mice expresses GSNOR. NOS1 and NOS2 were constitutively expressed in both strains of MSCs ( Fig. S2 E and F) , whereas NOS3 expression was absent from both strains (Fig. S2G) . Interestingly, NOS1 mRNA was ∼100-fold higher in GSNOR −/− mice (2.7 × 10 3 ± 3 × 10 2 absolute number of transcripts, ΔCt) compared with WT MSCs (2 × 10 4 ± 2 × 10 3 , P < 0.05; Fig. S2E ). Despite the up-regulation of NOS1, actual NO production, measured by 4,5-diamino-fluorescein diacetate (DAF-2DA), was nearly identical between the strains (Fig. S2H) . Thus, GSNOR deficiency up-regulates NOS1 but does not lead to increased NO production. tubes than those derived from WT mice ( Fig. 1 A-C) . To test whether this impairment was NO-mediated, we inhibited NO production in GSNOR −/− MSCs with the NO synthase inhibitor L-N G -nitroarginine methyl ester (L-NAME). This treatment completely normalized the number (49.9 ± 14.8, P < 0.001) and length (82.8 ± 20.5 μm, P < 0.001) of GSNOR −/− tubes ( Fig. 1 A-C), indicating that inhibition of NO production restores network formation by MSCs. L-NAME had no effect on WT MSC tube formation; however, treatment with the NO donors, S-nitrosoglutathione (GSNO) and S-nitroso-N-acetyl-D,L-penicillamine (SNAP), impaired tube formation (15.6 ± 9.0 and 31.8 ± 9.9, P < 0.001) and decreased tube length (98.4 ± 56.6 and 57.1 ± 24.9 μm, P < 0.001) by WT MSCs, confirming that small molecular weight S-nitrosothiols inhibit the vasculogenic potential of MSCs ( MSCs expressed VEGFR2, although its ligand VEGF-A was produced at similar levels by both strains (Fig. 2 A-D) . PDGFRα expression was diminished by ∼50% in GSNOR −/− MSCs as measured by FACS (Fig. 2 E-G), qRT-PCR (Fig. 2H) , and Western blotting ( Fig. 2 I and J) . The expression of PDGFRβ did not change (Fig. 2H) . Under physiologic conditions, MSCs express high levels of PDGFRα but not VEGFR2 (16) . Differentiation of MSC into endothelial cells requires activation of the PDGFRα by VEGF-A following a switch of receptors where VEGFR2 increases and PDGFRα decreases (19) . Together these findings support the paradigm that environments rich in bioavailable NO or genetic modifications (deletion of GSNOR) inhibit PDGFRα expression by MSCs resulting in impaired endothelial differentiation (Fig. 2K) . Furthermore, incubation with GSNO down-regulated PDGFRα by approximately twofold and up-regulated VEGF-A by ∼2.5-fold in WT MSCs, supporting the actions of lowmolecular-weight thiols in mediating this phenotype (Fig. S5A) . Finally, in GSNOR −/− MSCs, inhibition of NOS with L-NAME augmented VEGF-A production ∼4.5-fold (Fig. 3A) , demonstrating that NO levels modulate VEGF-A production. Activation of the GHRH receptor, with JI-38, a synthetic agonist, also increased VEGF-A production by 2.8-fold in GSNOR −/− MSCs (Fig. 3B ).
VEGF-A/PDGFR Signaling Is a Key in MSC-Mediated Vasculogenesis.
We next examined whether inhibition of PDGFRα, using a specific PDGFR IV antagonist (PIV), could reduce tube formation by MSCs. Treatment with PIV (0.1 μmol/L) impaired tube formation in both WT (∼2.6-fold; S6B ). However, the impact of PIV was much greater on GSNOR −/− tubes than WT. In addition, while treatment with L-NAME rescued tube formation by GSNOR −/− MSCs, PIV counteracted this effect, confirming that PDGFRα activation is required for tube formation by MSCs (Fig. 3 E and F; Fig. S6B ). Furthermore, when GSNOR −/− MSCs were treated with L-NAME, VEGF-A expression was significantly increased (Fig. 3A) , leading to enhanced tube formation through PDGFRα activation (Fig. 3 E  and F) , although mRNA expression of PDGFRα or β did not change following NOS inhibition.
Activation of VEGF-A Production with GHRH Agonists. As an alternative to NOS inhibition, we sought to augment VEGF-A production by activating the growth hormone-releasing hormone (GHRH) receptor, which was shown to be present on MSCs (Fig.  S7 A-C) . Stimulation of the GHRH receptor with the synthetic growth hormone-releasing hormone GHRH agonist JI-38 (20) or other potent GHRH agonists, MR-409 and MR-356 (Fig. S7 D-F) , also normalized the impaired tube formation by GSNOR −/− MSCs and did so to a similar extent as L-NAME (69 ± 11 tubes and 73 ± 33-μm tube length, P < 0.001; Fig. 3 ). Treatment with JI-38 and L-NAME in WT MSCs did not affect tube formation (Fig. 3 C and D; Fig. S3 A-C) , although stimulation of WT MSCs with JI-38 up-regulated VEGF-A expression by ∼2.5 fold (Fig.  S5B) . As with L-NAME, blockade of PDGFRα abolished the impact of this GHRH agonist (Fig. 3 E and F) . NO Signaling Impaired Vasculogenesis in Vivo. To confirm our in vitro data, we examined vasculogenesis in vivo by performing a Matrigel plug assay. GFP-labeled MSCs from WT and GSNOR −/− mice were injected s.c. into immunocompromised mice (NOD-SCID). Two weeks later, Matrigel plugs were harvested and assayed for immunofluorescence staining and determination of capillary formation (Fig. 4A) . MSCs from GSNOR −/− mice had impaired blood vessel formation compared with WT MSCs (1.84 ± 1.3 vs. 10.2 ± 2.7/mm 2 , P < 0.01; Fig. 4 A and B) . Furthermore, we determined the percentage of GFP-transduced MSCs that differentiated into endothelial cells and also formed blood vessels (Fig.  4 C and D) . GSNOR −/− MSCs exhibited diminished endothelial differentiation (7.7 ± 1.64% vs. 12.5 ± 1.0%, P < 0.02) as assessed by isolectin staining (in orange) colocalized with GFP and also reduced the number of GFP + blood vessels (0.4 ± 0.2 vs. 1.6 ± 0.4 mm 2 ) compared with WT MSCs . These results agree with our in vitro data and support the negative effect of NO signaling on vasculogenesis by MSCs.
NO Donors Impaired the Ability of Human Bone Marrow-Derived
MSCs to Form Capillary Tube-Like Structures in Vitro. We next tested whether human and mouse MSCs responded similarly to NO donors and observed that NO donors also reduced tube formation by hMSCs. Whereas the human cells formed a network more rapidly than murine cells (Fig. S8 ), hMSCs treated with NO donors GSNO or SNAP produced half as many tubes as vehicle-treated cells. Treatment with 10, 40, and 100 μmol/L GSNO reduced the number (26.6 ± 7.1, 24.8 ± 4.3, and 27.6 ± 4.0, respectively, vs. 49.2.0 ± 8.1, P < 0.001) and length (94.0 ± 34.3, 78.0 ± 41.0 and 85.0 ± 34.4, respectively, vs. 125.0 ± 52.6, P < 0.001) of tubes ( Fig. 5 A and B) . Similarly, treatment with 10 and 100 μmol/L SNAP reduced tube number (34.0 ± 6.1 and 25.0 ± 4.9 vs. 49.2 ± 8.1, P < 0.001) and length (82.0 ± 29.2 and 91.0 ± 32.2 vs. 128 ± 52 μm, P < 0.001) compared with untreated hMSCs. Similar to murine MSCs, inhibition of NOS with L-NAME had no effect on hMSC tube formation (Fig. 5 A and B) .
Finally, to test whether MSCs respond differently to endothelial cells, we used the Matrigel assay with human umbilical vein endothelial cells (HUVECs), and in contrast to mouse and human MSCs, HUVECs treated with NO donors (GSNO and SNAP) exhibited enhanced network formation, but NOS inhibition with 15 μmol/L L-NAME was not sufficient to reduce tube-like capillary structure formation (Fig. S9 A-C) . These experiments revealed that NO signaling has a negative impact on endothelial differentiation by MSCs in contrast to (human) endothelial cells where NO favors angiogenesis.
Discussion
The major finding shown in this work is that GSNOR signaling contributes to MSC-mediated vasculogenesis. We demonstrated this principle in a variety of ways. First, MSCs from GSNOR-deficient mice exhibited attenuated vasculogenesis both in vitro and in vivo. Similarly, S-nitrosothiol (SNO) donors diminished vasculogenesis in human MSCs. Pharmacological inhibition of NO in , enhanced vasculogenesis by MSCs. Importantly, the opposite effect was shown to be true for HUVECs in which NO enhanced vascular tube formation. Together, these findings reveal a unique, paradoxical mode of vascular regulation between MSCs and endothelial cells and suggest that MSC-mediated vascular formation may increase in states of NO deficiency. Importantly, the simultaneous potentiation of EPC-and inhibition of MSCmediated vasculogenesis by NO may represent a mechanism for preserving MSC regulatory capacity in an environment of enhanced EPC vascular formation.
NO signaling in MSCs has heretofore not been examined. The present study revealed that GSNOR deficiency impairs MSCmediated postnatal vasculogenesis. Previously, we and others showed that GSNOR is a key regulator of cardiovascular function and vascular tone, regulating a dynamic nitrosylation/denitrosylation cycle of proteins (21, 22) . We chose to investigate S-nitrosylation as the primary signaling mode exerting NO bioactivity and took advantage of the fact that both excessive NO production by NOS activation or reduced SNO metabolism due to GSNOR deficiency enhances S-nitrosylation (23). Accordingly, we used MSCs from the GSNOR −/− as the primary mode of investigating NO/SNO signaling in these stem cells.
At the mechanistic level, our studies reveal that the underlying basis by which NO signaling through GSNOR directly affects MSC vasculogenesis appears to be regulation of PDGFRα abundance (Fig. 2K ). Bone marrow MSCs, which do not express VEGFR2 (16), respond to VEGF-A through a PDGFR-ligand interaction (16, 24, 25) . Here we show that GSNOR −/− MSCs have reduced expression of PDGFRα, which is causally linked to impaired endothelial differentiation. Importantly, treatment with L-NAME rescued capillary network formation from GSNOR −/− MSCs by increasing VEGF-A production followed by activation of PDGFRα. However, this effect was not observed in WT MSCs when similarly treated with L-NAME, which may represent cell type differences in dose response. Human MSCs cocultured with endothelial cells differentiate into endothelial-like cells, and this process can be inhibited by VEGF-A antisera (26), corroborating our finding that VEGF-A is crucial for MSC-mediated vasculogenesis. In our study, we demonstrated clearly that VEGF-A/ PDGFRα directly affected MSC fate decisions, although we cannot discount that the interactions between MSCs and endothelial cells are crucial for vascular homeostasis and repair. In this respect, MSCs are thought to be intimately involved with vascular homeostasis throughout the body, preserving vascular integrity by differentiating to pericytes (9, 27) . We also used a second strategy to test whether VEGF-A signaling rescued diminished vasculogenesis by GSNOR −/− MSCs. Based on our previous observations, that the activation of GHRH receptors leads to an increased VEGF-A in vivo (28), we used GHRH agonists. Indeed these agonists normalized vasculogenesis in a PDGFRα-dependent manner. These findings have important implications for the therapeutic application of GHRH agonists to ischemic disorders. We previously showed that GHRH agonists improve cardiac structure and function after myocardial infarction (28, 29) . These findings shed further light on the beneficial effects of GHRH agonists on wound healing (30) and the maintenance of pancreatic β islets (31).
Our results confirmed that NO signaling through small-molecular-weight thiols is an important regulator of vasculogenesis in MSCs. More specifically, we found that endothelial differentiation is impaired in GSNOR −/− MSCs in vivo, suggesting that GSNOR represents a valuable pharmacologic target for regulation of neovascularization. Moreover, our results support that S-nitrosylation plays an important role in MSC-mediated vasculogenesis and may affect cell fate decisions. Importantly, Lima et al. (22) showed that myocardial infarction size is reduced in GSNOR −/− mice, an effect that was associated with enhanced neovascularization, suggesting that neovascularization in that setting is primarily a result of EPC activation.
In addition, we demonstrated that decreased production of NO enhanced tube-like formation on Matrigel in vitro. This result was illustrated by the increased tube formation by MSCs from NOS2 −/− mice, the normalization of tube formation by treatment of GSNOR −/− MSCs with L-NAME, and ultimately, the reduction in tube formation in WT mMSCs and in hMSCs treated with NO donors, indicating a cross-species effect.
Therefore, deficiency of NO has a positive impact on MSCmediated vasculogenesis. In agreement with our data, Wang et al. (32) demonstrated that treatment of human MSCs with NO donors suppresses production of the proangiogenic factors VEGF and hepatocyte growth factor. Moreover, bone marrowderived MSCs isolated from patients with systemic sclerosis, a disease characterized by NO overproduction, vascular dysfunction, and systemic fibrosis, have impaired endothelial cell differentiation (33) , consistent with our findings that environments rich in NO impair postnatal vasculogenesis by MSCs. Together, these findings suggest a reduced regenerative capacity of MSCs in nitroso/redox unbalanced environments such as heart failure, sepsis, and neuronal degenerative diseases (34) . Furthermore, NO may attenuate the protection by MSCs in ischemic myocardium by serving as a natural braking mechanism for MSC-induced neovascularization in a tissue recovering from ischemic injury.
We showed that NO synthases, NOS1 and NOS2, but not NOS3, were constitutively expressed in MSCs. Importantly, MSCs from WT and GSNOR −/− mice had equivalent NO production; however, NOS1 expression was up-regulated in GSNOR −/− MSCs, presumably to maintain NO production at physiologic levels. Unlike MSCs, endothelial cells express the NOS3 isoform (35) shown to participate in proangiogenic signaling (36) . Additionally, NOS3 and GSNOR play an important role in endothelial cell-mediated postnatal angiogenesis and vascular tone (21, 22) . Moreover, GSNOR −/− mice have augmented myocardial capillary density, at baseline, as shown by CD31 staining (22) , suggesting that S-nitrosylation enhances angiogenesis by endothelial cells in contrast to the inhibitory effect on MSCs. We observed a similar effect in murine and human MSCs compared with endothelial cells (HUVECs), suggesting that NO promotes angiogenesis by endothelial cells and inhibits vasculogenesis by MSC. Moreover, pathological conditions such as endothelial dysfunction where there is reduced NO bioavailability (37) may trigger vasculogenesis by MSC, perhaps serving as a compensatory mechanism.
In summary, our findings offer insight regarding the role of NO in vascular biology in which environments that are NO deficient trigger the participation of MSCs in vasculogenesis. Thus, NO exerts a balanced effect on the different cellular precursors participating in neo-angiogenesis, promoting that portion mediated by EPCs while simultaneously inhibiting that originating with MSC-like cells. These findings offer exciting insights into the pathophysiology of conditions characterized by exuberant neo-vascularization such as cancer and diabetic retinopathy and, as such, have therapeutic implications.
Materials and Methods
A detailed description of the materials and methods can be found in SI Materials and Methods. Briefly, GSNOR −/− mice were generated as described (18) and compared with age-and sex-matched NOS2 −/− and WT mice (C57BL/ 6). Bone marrow-derived MSCs isolated and expanded from WT, GSNOR −/− , and NOS2 −/− mice and humans (hMSCs) were grown in endothelial growth media (EGM-2; Lonza) followed by 24 h in Matrigel, in the presence of vehicle, L-NAME [an NO synthase (NOS) inhibitor], GSNO, and SNAP (NO donors), and JI-38 (20) , a GHRH agonist. GHRH agonists, JI-38, MR-409, and MR-356 were synthesized in the laboratory of A.V.S. NO production and NOS expression by MSCs was assessed. Additionally, we used an allograft assay to study in vivo vasculogenesis by murine MSCs. All animal protocols and experimental procedures were approved by the University of Miami Institutional Animal Care and Use Committee. Data were analyzed for significance using one-way ANOVA, the TukeyKramer multiple comparisons test, and Student t test. All analyses were performed using GraphPad Prism, version 4.03, and P < 0.05 was considered significant. All data were presented as mean ± SE. A and B) . Quantification of the (A) number and (B) length (μm) of tube-like structures following 6-h exposure to no treatment, vehicle, L-NAME, GSNO, or SNAP (n ≥ 3, *P < 0.05 vs. hMSCS ± vehicle).
